-
Signature
-
/s/ Vijay Iyer, Attorney-in-Fact
-
Issuer symbol
-
BKNG
-
Transactions as of
-
17 Nov 2025
-
Net transactions value
-
-$2,135,414
-
Form type
-
4
-
Filing time
-
19 Nov 2025, 07:30:08 UTC
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| Fogel Glenn D |
CEO AND PRESIDENT, Director |
BOOKING HOLDINGS INC., 800 CONNECTICUT AVENUE, NORWALK |
/s/ Vijay Iyer, Attorney-in-Fact |
19 Nov 2025 |
0001516908 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
BKNG |
Common Stock |
Sale |
$47,752 |
-10 |
-0.04% |
$4775.17 |
22,584 |
17 Nov 2025 |
Direct |
F1, F2 |
| transaction |
BKNG |
Common Stock |
Sale |
$95,549 |
-20 |
-0.09% |
$4777.43 |
22,564 |
17 Nov 2025 |
Direct |
F1 |
| transaction |
BKNG |
Common Stock |
Sale |
$95,927 |
-20 |
-0.09% |
$4796.35 |
22,544 |
17 Nov 2025 |
Direct |
F1, F3 |
| transaction |
BKNG |
Common Stock |
Sale |
$47,988 |
-10 |
-0.04% |
$4798.75 |
22,534 |
17 Nov 2025 |
Direct |
F1 |
| transaction |
BKNG |
Common Stock |
Sale |
$129,614 |
-27 |
-0.12% |
$4800.52 |
22,507 |
17 Nov 2025 |
Direct |
F1, F4 |
| transaction |
BKNG |
Common Stock |
Sale |
$312,128 |
-65 |
-0.29% |
$4801.97 |
22,442 |
17 Nov 2025 |
Direct |
F1, F5 |
| transaction |
BKNG |
Common Stock |
Sale |
$144,124 |
-30 |
-0.13% |
$4804.12 |
22,412 |
17 Nov 2025 |
Direct |
F1, F6 |
| transaction |
BKNG |
Common Stock |
Sale |
$48,062 |
-10 |
-0.04% |
$4806.22 |
22,402 |
17 Nov 2025 |
Direct |
F1 |
| transaction |
BKNG |
Common Stock |
Sale |
$48,086 |
-10 |
-0.04% |
$4808.58 |
22,392 |
17 Nov 2025 |
Direct |
F1 |
| transaction |
BKNG |
Common Stock |
Sale |
$96,254 |
-20 |
-0.09% |
$4812.71 |
22,372 |
17 Nov 2025 |
Direct |
F1, F7 |
| transaction |
BKNG |
Common Stock |
Sale |
$48,137 |
-10 |
-0.04% |
$4813.74 |
22,362 |
17 Nov 2025 |
Direct |
F1 |
| transaction |
BKNG |
Common Stock |
Sale |
$48,222 |
-10 |
-0.04% |
$4822.16 |
22,352 |
17 Nov 2025 |
Direct |
F1 |
| transaction |
BKNG |
Common Stock |
Sale |
$144,723 |
-30 |
-0.13% |
$4824.10 |
22,322 |
17 Nov 2025 |
Direct |
F1, F8 |
| transaction |
BKNG |
Common Stock |
Sale |
$144,808 |
-30 |
-0.13% |
$4826.95 |
22,292 |
17 Nov 2025 |
Direct |
F1, F9 |
| transaction |
BKNG |
Common Stock |
Sale |
$48,302 |
-10 |
-0.04% |
$4830.21 |
22,282 |
17 Nov 2025 |
Direct |
F1 |
| transaction |
BKNG |
Common Stock |
Sale |
$48,319 |
-10 |
-0.04% |
$4831.94 |
22,272 |
17 Nov 2025 |
Direct |
F1 |
| transaction |
BKNG |
Common Stock |
Sale |
$48,357 |
-10 |
-0.04% |
$4835.72 |
22,262 |
17 Nov 2025 |
Direct |
F1 |
| transaction |
BKNG |
Common Stock |
Sale |
$53,227 |
-11 |
-0.05% |
$4838.78 |
22,251 |
17 Nov 2025 |
Direct |
F1, F10 |
| transaction |
BKNG |
Common Stock |
Sale |
$48,409 |
-10 |
-0.04% |
$4840.94 |
22,241 |
17 Nov 2025 |
Direct |
F1 |
| transaction |
BKNG |
Common Stock |
Sale |
$48,480 |
-10 |
-0.04% |
$4847.98 |
22,231 |
17 Nov 2025 |
Direct |
F1 |
| transaction |
BKNG |
Common Stock |
Sale |
$96,983 |
-20 |
-0.09% |
$4849.14 |
22,211 |
17 Nov 2025 |
Direct |
F1 |
| transaction |
BKNG |
Common Stock |
Sale |
$48,570 |
-10 |
-0.05% |
$4856.95 |
22,201 |
17 Nov 2025 |
Direct |
F1 |
| transaction |
BKNG |
Common Stock |
Sale |
$97,301 |
-20 |
-0.09% |
$4865.06 |
22,181 |
17 Nov 2025 |
Direct |
F1, F11 |
| transaction |
BKNG |
Common Stock |
Sale |
$48,678 |
-10 |
-0.05% |
$4867.82 |
22,171 |
17 Nov 2025 |
Direct |
F1 |
| transaction |
BKNG |
Common Stock |
Sale |
$97,415 |
-20 |
-0.09% |
$4870.76 |
22,151 |
17 Nov 2025 |
Direct |
F1, F12 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: